Evidence map›Paper›PMID 39619166›Full record

ArticleTherapeutic advances in chronic disease2024

Association between galectin-3 and hepatosteatosis in a community-based cross-sectional study.

Ming-Shyan Lin, Ya-Chi Tu, Yu-Sheng Lin, Meng-Hung Lin, Chun-Liang Lin, Ming-Horng Tsai, Yung-Yu Hsieh, Tien-Hsing Chen, Mei-Yen Chen, Chung-Sheng Shi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in chronic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The Role of Galectin-3 in Liver Inflammation and Fibrosis.Journal of inflammation research · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ming-Shyan LinDepartments of Internal Medicine and Cardiology, Chang Gung Memorial Hospital, Chiayi, Taiwan.ORCID https://orcid.org/0000-0001-9348-8153
Ya-Chi TuDepartment of Laboratory Medicine, New Taipei Municipal Tucheng Hospital, New Taipei City, Taiwan.
Yu-Sheng LinDepartments of Internal Medicine and Cardiology, Chang Gung Memorial Hospital, Chiayi, Taiwan.
Meng-Hung LinHealth Information and Epidemiology Laboratory, Chang Gung Memorial Hospital Chiayi Branch, Chiayi, Taiwan.
Chun-Liang LinDepartment of Nephrology, Chang Gung Memorial Hospital, Chiayi, Taiwan.
Ming-Horng TsaiDepartment of Pediatrics, Chang Gung Memorial Hospital, Yunlin, Taiwan.
Yung-Yu HsiehDepartment of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Chiayi, Taiwan.
Tien-Hsing ChenDepartments of Internal Medicine and Cardiology, Chang Gung Memorial Hospital Chiayi Branch, Keelung, Taiwan.
Mei-Yen ChenDepartment of Nursing, Chang Gung University of Science and Technology, Chiayi, Taiwan.
Chung-Sheng ShiGraduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, No. 6, Sec. West, Chai-Pu Road, Pu-TZ City, Chiayi 61363, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatosteatosis is a common condition that can lead to cirrhosis and liver cancer. Galectin-3 (GAL-3) has been implicated in liver fibrosis and inflammation. Objectives: The purpose of this study was to investigate the association between GAL-3 and hepatosteatosis. Design: This study is a retrospective secondary analysis of data from a community health screening program. Methods: A total of 766 participants were included in the final analysis. Hepatosteatosis was diagnosed using ultrasonography, and GAL-3 levels were measured using enzyme-linked immunosorbent assay. Logistic regression analysis was used to examine the association between GAL-3 levels and the presence of hepatosteatosis, adjusting for age, sex, and other potential confounding factors. Results: The prevalence of moderate-to-severe hepatosteatosis in the study population was 31.5%. The participants with hepatosteatosis had a significantly higher mean level of GAL-3 compared to those without hepatosteatosis (16.6 ± 7.3 vs 13.5 ± 7.3 ng/ml; Conclusion: Our findings suggest that GAL-3 level is significantly associated with the presence of moderate-to-severe hepatosteatosis, independent of other known cardiometabolic risk factors.

Indexed as

ALT/AST ratiogalectin-3hepatosteatosismetabolic syndromewaist-to-height ratio

Identifiers

PMID39619166
PMCPMC11608448

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.